Exemestane a new steroidal aromatase inhibitor of clinical relevance

Research published in 2011 showed that Aromasin can lower risk in high-risk, postmenopausal women who've never been diagnosed with breast cancer. Aromasin is not approved by the FDA for this use, but doctors may consider it a good alternative to tamoxifen or Evista. In 2013, the American Society of Clinical Oncology (ASCO) released new guidelines on using hormonal therapy medicines to reduce breast cancer risk in high-risk women. These guidelines recommend that doctors talk to high-risk postmenopausal women about using Aromasin to reduce risk. ASCO is a national organization of oncologists and other cancer care providers. ASCO guidelines give doctors recommendations for treatments that are supported by much credible research and experience.

A number of investigators have reported on a rather rare syndrome of excess aromatase activity. In boys, it can lead to gynecomastia , and in girls to precocious puberty and gigantomastia . In both sexes, early epiphyseal closure leads to short stature. This condition is due to mutations in the CYP19A1 gene which encodes aromatase. [16] It is inherited in an autosomal dominant fashion. [17] It has been suggested that the pharaoh Akhenaten and other members of his family may have suffered from this disorder, [18] but more recent genetic tests suggest otherwise. [19] It is one of the causes of familial precocious puberty—a condition first described in 1937. [20]

Exemestane a new steroidal aromatase inhibitor of clinical relevance

exemestane a new steroidal aromatase inhibitor of clinical relevance

Media:

exemestane a new steroidal aromatase inhibitor of clinical relevanceexemestane a new steroidal aromatase inhibitor of clinical relevanceexemestane a new steroidal aromatase inhibitor of clinical relevanceexemestane a new steroidal aromatase inhibitor of clinical relevanceexemestane a new steroidal aromatase inhibitor of clinical relevance